| scholarly article | Q13442814 |
| P50 | author | Howard E. Gendelman | Q64858836 |
| Christopher Destache | Q43152295 | ||
| P2093 | author name string | Jay A Nelson | |
| Michael D Boska | |||
| R Lee Mosley | |||
| Eric J Benner | |||
| Travis B Lewis | |||
| Mariano Uberti | |||
| P2860 | cites work | T cell deficiency leads to cognitive dysfunction: implications for therapeutic vaccination for schizophrenia and other psychiatric conditions | Q24562400 |
| Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis | Q24681228 | ||
| Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure | Q28145614 | ||
| Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease | Q28187904 | ||
| Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains | Q29616293 | ||
| Parkinson's disease. First of two parts | Q29620416 | ||
| Basal ganglia metabolite concentrations in idiopathic Parkinson's disease and multiple system atrophy measured by proton magnetic resonance spectroscopy | Q30622383 | ||
| Proton MR spectroscopic imaging of the striatum in Parkinson's disease | Q67218938 | ||
| Histochemical detection of apoptosis in Parkinson's disease. | Q67401850 | ||
| Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine | Q70951248 | ||
| Changes in N-acetyl-aspartate content during focal and global brain ischemia of the rat | Q72333925 | ||
| Assessment of disease severity in parkinsonism with fluorine-18-fluorodeoxyglucose and PET | Q72616594 | ||
| Accumulation of N-acetyl-L-aspartate in the brain of the tremor rat, a mutant exhibiting absence-like seizure and spongiform degeneration in the central nervous system | Q73812124 | ||
| Vaccination with dendritic cells pulsed with peptides of myelin basic protein promotes functional recovery from spinal cord injury | Q79080347 | ||
| Magnetic resonance spectroscopy in Alzheimer's disease: focus on N-acetylaspartate | Q30641047 | ||
| Java-based graphical user interface for MRUI, a software package for quantitation of in vivo/medical magnetic resonance spectroscopy signals | Q30665733 | ||
| A comprehensive review of proton magnetic resonance spectroscopy studies in dementia and Parkinson's disease. | Q30708048 | ||
| Functional imaging in Parkinson's disease: activation studies with PET, fMRI and SPECT. | Q30795851 | ||
| Use of functional imaging in Parkinsonism and dementia | Q30880503 | ||
| Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system | Q30885534 | ||
| Localized striatal delivery of GDNF as a treatment for Parkinson disease | Q31038741 | ||
| N-acetyl aspartate: a marker for neuronal loss or mitochondrial dysfunction | Q31997000 | ||
| A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson's disease. | Q32016206 | ||
| The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety | Q32133943 | ||
| Improved method for accurate and efficient quantification of MRS data with use of prior knowledge | Q32172320 | ||
| Antigenic specificity of immunoprotective therapeutic vaccination for glaucoma | Q33187884 | ||
| A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease | Q33292093 | ||
| Etiology and pathogenesis of Parkinson's disease | Q33593402 | ||
| Passive or active immunization with myelin basic protein promotes recovery from spinal cord contusion. | Q33915855 | ||
| Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease | Q33952130 | ||
| Vaccination with a Nogo-A-derived peptide after incomplete spinal-cord injury promotes recovery via a T-cell-mediated neuroprotective response: comparison with other myelin antigens | Q33953007 | ||
| Morphological and functional imaging studies on the diagnosis and progression of Parkinson's disease | Q34035630 | ||
| Pathoanatomy of Parkinson's disease | Q34035667 | ||
| Cytokines in Parkinson's disease | Q34112474 | ||
| Psychiatric complications in Parkinson's disease | Q34155177 | ||
| Automatic, localized in vivo adjustment of all first- and second-order shim coils | Q34352735 | ||
| Psychiatric complications in the treatment of Parkinson's disease | Q34366920 | ||
| Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy | Q34486849 | ||
| Systematic review of proton magnetic resonance spectroscopy of the striatum in parkinsonian syndromes | Q34488986 | ||
| Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma | Q34734517 | ||
| Dual action of glatiramer acetate (Cop-1) in the treatment of CNS autoimmune and neurodegenerative disorders | Q34735243 | ||
| Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking | Q34830749 | ||
| NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease | Q35022998 | ||
| Inflammation and therapeutic vaccination in CNS diseases | Q35030005 | ||
| Rare genetic mutations shed light on the pathogenesis of Parkinson disease | Q35047289 | ||
| In vivo gene delivery of glial cell line--derived neurotrophic factor for Parkinson's disease | Q35094906 | ||
| T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies | Q35160575 | ||
| Neuroprotection in Parkinson disease | Q35186753 | ||
| Novel anti-inflammatory therapy for Parkinson's disease. | Q35198023 | ||
| Selective accumulation of MPP+ in the substantia nigra: a key to neurotoxicity? | Q48535264 | ||
| Proton magnetic resonance spectroscopy in Parkinson's disease and atypical parkinsonian disorders | Q48586206 | ||
| Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration | Q48622307 | ||
| Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. | Q48806014 | ||
| An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease | Q49021986 | ||
| Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. | Q51593326 | ||
| Frontal lobe neuronal injury correlates to altered function in FIV-infected cats. | Q52536775 | ||
| Effects of fatigue on physical activity and function in patients with Parkinson's disease. | Q53727211 | ||
| Early differential diagnosis of Parkinson's disease with 18F-fluorodeoxyglucose and positron emission tomography. | Q54159517 | ||
| Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease | Q56567926 | ||
| The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system | Q58302057 | ||
| ??? | Q64777197 | ||
| Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease | Q35320917 | ||
| Looking Backward to Move Forward: Early Detection of Neurodegenerative Disorders | Q35573431 | ||
| Treatments of Parkinson disease: circa 2003. | Q35607910 | ||
| Different patterns of N-acetylaspartate loss in subcortical ischemic vascular dementia and AD. | Q35677181 | ||
| Chimeric dopamine-norepinephrine transporters delineate structural domains influencing selectivity for catecholamines and 1-methyl-4-phenylpyridinium | Q35993022 | ||
| 2D 1H spectroscopic imaging of the human brain at 4.1 T. | Q36730519 | ||
| WET, a T1- and B1-insensitive water-suppression method for in vivo localized 1H NMR spectroscopy | Q36733725 | ||
| Molar quantitation of in vivo proton metabolites in human brain with 3D magnetic resonance spectroscopic imaging | Q36736849 | ||
| A review of the clinical efficacy profile of copolymer 1: new U.S. phase III trial data | Q36838003 | ||
| Unchanged basal ganglia N-acetylaspartate and glutamate in idiopathic Parkinson's disease measured by proton magnetic resonance spectroscopy | Q36862019 | ||
| Early detection and longitudinal changes in amyotrophic lateral sclerosis by (1)H MRSI. | Q37322633 | ||
| Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity | Q37683630 | ||
| Effect of MPTP-induced denervation on basal ganglia GABA(B) receptors: correlation with dopamine concentrations and dopamine transporter | Q38301952 | ||
| Ethanol and the nervous system | Q38674639 | ||
| The pH dependence of tritium exchange with the C-2 protons of the histidines in bovine trypsin | Q39106577 | ||
| Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism | Q39111952 | ||
| Relation between clinical characteristics of Parkinson's disease and cognitive decline | Q40603373 | ||
| Nasal vaccination with beta-amyloid peptide for the treatment of Alzheimer's disease | Q40666797 | ||
| Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS. | Q40781605 | ||
| Neuroprotection by encephalomyelitis: rescue of mechanically injured neurons and neurotrophin production by CNS-infiltrating T and natural killer cells. | Q40869638 | ||
| Cop 1 as a candidate drug for multiple sclerosis | Q41573853 | ||
| Automated image registration: I. General methods and intrasubject, intramodality validation | Q41795259 | ||
| Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter. | Q42468902 | ||
| Nigral and striatal comparative study of the neurotoxic action of 1-methyl-4-phenylpyridinium ion: involvement of dopamine uptake system | Q42521977 | ||
| Vaccination for neuroprotection in the mouse optic nerve: implications for optic neuropathies. | Q43517448 | ||
| Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum | Q43691648 | ||
| Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. | Q43715960 | ||
| N-Acetylaspartate reduction as a measure of injury severity and mitochondrial dysfunction following diffuse traumatic brain injury | Q43784506 | ||
| Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. | Q43906992 | ||
| Proton MR spectroscopic imaging in multiple sclerosis | Q43953217 | ||
| Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. | Q44086465 | ||
| Proton magnetic resonance imaging and spectroscopy identify metabolic changes in the striatum in the MPTP feline model of parkinsonism | Q44346048 | ||
| Attenuation of MPTP-induced neurotoxicity and behavioural impairment in NSE-XIAP transgenic mice. | Q44384547 | ||
| Utility of cerebral proton magnetic resonance spectroscopy in differential diagnosis of HIV-related dementia. | Q44465500 | ||
| Proton MR spectroscopic changes in Parkinson's diseases after thalamotomy | Q44555350 | ||
| N-acetyl aspartate estimation: a potential method for determining neuronal loss in the transmissible spongiform encephalopathies | Q44594914 | ||
| Hippocampal N-acetyl aspartate levels do not mirror neuronal cell densities in creatine-supplemented epileptic rats | Q44658205 | ||
| Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations | Q45302799 | ||
| Chronic D1 and D2 dopaminomimetic treatment of MPTP-denervated monkeys: effects on basal ganglia GABA(A)/benzodiazepine receptor complex and GABA content | Q48165059 | ||
| FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. | Q48230911 | ||
| Differential vulnerability of dopamine receptors in the mouse brain treated with MPTP. | Q48241892 | ||
| Mechanisms of cell death in Alzheimer disease--immunopathology. | Q48330745 | ||
| Understanding cell death in Parkinson's disease | Q48389460 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Parkinson's disease | Q11085 |
| immunization | Q1415366 | ||
| P304 | page(s) | 1691-1700 | |
| P577 | publication date | 2005-02-01 | |
| P1433 | published in | Journal of Neuroscience | Q1709864 |
| P1476 | title | Quantitative 1H magnetic resonance spectroscopic imaging determines therapeutic immunization efficacy in an animal model of Parkinson's disease | |
| P478 | volume | 25 |
| Q47860582 | 1H Spectroscopic Imaging of the Rodent Brain |
| Q46748023 | A possible role for humoral immunity in the pathogenesis of Parkinson's disease |
| Q48468237 | An in vivo ultrahigh field 14.1 T (1) H-MRS study on 6-OHDA and α-synuclein-based rat models of Parkinson's disease: GABA as an early disease marker |
| Q33815568 | BCG vaccine-induced neuroprotection in a mouse model of Parkinson's disease |
| Q34762041 | BL-1023 improves behavior and neuronal survival in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-intoxicated mice |
| Q37366637 | Comparison of analytical mathematical approaches for identifying key nuclear magnetic resonance spectroscopy biomarkers in the diagnosis and assessment of clinical change of diseases |
| Q37015408 | Debate: "is increasing neuroinflammation beneficial for neural repair?". |
| Q34344365 | Dimethyl sulfoxide (DMSO) as a potential contrast agent for brain tumors. |
| Q39809303 | Effect of glatiramer acetate on short-term memory impairment induced by lipopolysaccharide in male mice. |
| Q36234361 | Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action |
| Q33892744 | Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson's disease |
| Q36963184 | Mechanism of action of glatiramer acetate in treatment of multiple sclerosis |
| Q48393298 | Metabolic changes detected by ex vivo high resolution 1H NMR spectroscopy in the striatum of 6-OHDA-induced Parkinson's rat. |
| Q46844307 | Metabolic changes detected by proton magnetic resonance spectroscopy in vivo and in vitro in a murin model of Parkinson's disease, the MPTP-intoxicated mouse |
| Q26999015 | Metabolic disturbances in diseases with neurological involvement |
| Q33726019 | Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. |
| Q42908536 | Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's Disease |
| Q39060890 | Neurometabolic profiles of the substantia nigra and striatum of MPTP-intoxicated common marmosets: An in vivo proton MRS study at 9.4 T. |
| Q37741285 | Pharmacological therapy in Parkinson's disease: focus on neuroprotection |
| Q34372998 | Preclinical (1)H-MRS neurochemical profiling in neurological and psychiatric disorders |
| Q36088218 | Quantitative diffusion tensor imaging detects dopaminergic neuronal degeneration in a murine model of Parkinson's disease |
| Q34639915 | Registered bioimaging of nanomaterials for diagnostic and therapeutic monitoring |
| Q36525175 | The application of NMR-based metabonomics in neurological disorders |
| Q34245104 | The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice |
| Q38166155 | The role of innate and adaptive immunity in Parkinson's disease |
| Q31126472 | Whole-Brain Microscopy Meets In Vivo Neuroimaging: Techniques, Benefits, and Limitations. |
Search more.